Top 5 Breakthrough Pharmaceutical Drugs of the Decade

This article presents an overview of Top 5 Breakthrough Pharmaceutical Drugs of the Decade. For a detailed overview of the 20 Breakthrough Pharmaceutical Drugs of the Decade  with insights into peak sales estimate at the time of approval by FDA, read our article Top 20 Breakthrough Pharmaceutical Drugs of the Decade.

5. Opdualag

Peak Sales Estimate at the Time of Approval (USD Billion): 4

Disease: Melanoma

Company: Bristol Myers Squibb

Bristol Myers Squibb’s new LAG-3 antibody relatlimab, approved in a fixed-dose combination with Opdivo for unresectable or metastatic melanoma under the brand name Opdualag, is growing and gathering market share. OPDUALAG is administered through a vein via intravenous infusion, typically by a healthcare professional, once every four weeks. The infusion process for OPDUALAG takes approximately 30 minutes. The effectiveness of OPDUALAG was assessed by monitoring duration during which tumors showed no signs of growth following the treatment, known as progression-free survival (PFS). Opdualag revenues grew nearly threefold to $154 million globally in Q2 2023, compared to $58 million in Q2 2022, the first quarter the drug was on the market.